Related references
Note: Only part of the references are listed.Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children
Ralf Knoefler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Experience with ponatinib in paediatric patients with leukaemia
Jenna Rossoff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia
Fiorina Giona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia
Graeme Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Claudia Vener et al.
BLOOD ADVANCES (2020)
Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2020)
How I treat chronic myeloid leukemia in children and adolescents
Nobuko Hijiya et al.
BLOOD (2019)
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
Marc G. Berger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia
Nobuko Hijiya et al.
BLOOD (2019)
Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
Himalee S. Sabnis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)
Haruko Shima et al.
BLOOD (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
Adrian G. Minson et al.
BLOOD ADVANCES (2019)
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
Preetesh Jain et al.
BLOOD ADVANCES (2019)
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Lia Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia
Thomas Ernst et al.
LEUKEMIA (2018)
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
Meinolf Suttorp et al.
LEUKEMIA (2018)
Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls
R. de Cassia Viu Carrara et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis et al.
PEDIATRIC BLOOD & CANCER (2016)
The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors
Fabio Efficace et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years
Josu de la Fuente et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2014)
Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A
Der-Cherng Liang et al.
BLOOD (2013)
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis
Karthik R. Narayanan et al.
PEDIATRIC BLOOD & CANCER (2013)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
Frederic Millot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Imatinib mesylate causes growth plate closure in vivo
K. Vandyke et al.
LEUKEMIA (2009)
Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome
T Seshadri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ST1571 (Gleevec (TM)) as a paradigm for cancer therapy
BJ Druker
TRENDS IN MOLECULAR MEDICINE (2002)
Share Paper
